Retatrutide 20mg (Lyophilized Peptide)
Intended Use: Laboratory Research Only (Not for Human Consumption)
$95.00
Product Overview
Retatrutide (LY3437943) is an advanced, highly potent single-molecule triple agonist. It simultaneously targets the receptors for glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. This novel mechanism of action works synergistically to regulate nutrient metabolism, decrease food intake, and increase energy expenditure.
Disclaimer: This 20mg formulation is intended strictly for in-vitro study and laboratory research. In current human clinical trials, the maximum dosage evaluated is 12mg weekly.
Clinical Research and Efficacy
Recent phase 3 clinical data and subsequent meta-analyses have highlighted the profound metabolic effects of retatrutide. Systematic reviews demonstrate that retatrutide produces significant reductions in body weight, body mass index (BMI), and waist circumference, while also yielding substantial improvements in glycemic control and lipid profiles compared to a placebo (Abdrabou Abouelmagd et al., 2025). By activating three distinct hormone receptors simultaneously, retatrutide has been shown to be statistically superior to existing single and dual agonists in managing obesity-related metrics (Tewari et al., 2025).
Specifications
Molecular Formula: C223H343N46O70
Molecular Weight: 4731.3 g/mol
Format: Lyophilized powder
Storage Guidelines: Store at -20°C. Keep away from direct light. Avoid repeated freeze-thaw cycles once reconstituted.